Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-54. (Cancelled)

55. (New) An immunogenic polypeptide comprising a human IgE CH3 domain located between two non-placental mammalian IgE domains, wherein said immunogenic polypeptide is effective to induce an anti-human IgE response in a human.

56. (New) The immunogenic polypeptide of claim 55, wherein each of said two non-placental mammalian IgE domains has an IgE sequence present in a non-placental mammal selected from the group consisting of opossum, platypus, koala, kangaroo, wallaby, and wombat.

57. (New) The immunogenic polypeptide of claim 55, wherein one of said two non-placental mammalian IgE domains is a non-placental mammalian IgE CH2 domain.

58. (New) The immunogenic polypeptide of claim 55, wherein one of said two non-placental mammalian IgE domains is a non-placental mammalian IgE CH4 domain.

59. (New) The immunogenic polypeptide of claim 55, wherein one of said two non-placental mammalian IgE domains is a non-placental mammalian IgE CH2 domain, and the other of said two non-placental mammalian IgE domains is a non-placental mammalian IgE CH4 domain.

60. (New) The immunogenic polypeptide of claim 55, wherein one of said two non-placental mammalian IgE domains is an opossum IgE CH2 domain.

61. (New) The immunogenic polypeptide of claim 55, wherein one of said two non-placental mammalian IgE domains is an opossum IgE CH4 domain.

62. (New) The immunogenic polypeptide of claim 55, wherein one of said two non-placental mammalian IgE domains is an opossum IgE CH2 domain, and the other of said two non-placental mammalian IgE domains is an opossum IgE CH4 domain.

63. (New) The immunogenic polypeptide of claim 55, wherein the sequence of said immunogenic polypeptide is as set forth in SEQ ID NO:8.

64. (New) The immunogenic polypeptide of claim 55, wherein said immunogenic polypeptide comprises two human IgE CH3 domains and three non-placental mammalian IgE domains.

65. (New) The immunogenic polypeptide of claim 64, wherein, in an N-terminal to C-terminal direction, a first of said three non-placental mammalian IgE domains is followed by a first of said two human IgE CH3 domains which is followed by a second of said three non-placental mammalian IgE domains which is followed by a second of said two human IgE CH3 domains which is followed by a third of said three non-placental mammalian IgE domains.

66. (New) The immunogenic polypeptide of claim 65, wherein said first of said three non-placental mammalian IgE domains is an opossum IgE CH2 domain, wherein said second of said three non-placental mammalian IgE domains is an opossum IgE CH2 domain, and wherein said third of said three non-placental mammalian IgE domains is an opossum IgE CH4 domain.

67. (New) The immunogenic polypeptide of claim 55, wherein said immunogenic polypeptide comprises four human IgE CH3 domains and three non-placental mammalian IgE domains.

68. (New) The immunogenic polypeptide of claim 67, wherein, in an N-terminal to C-terminal direction, a first of said three non-placental mammalian IgE domains is followed by a

first of said four human IgE CH3 domains which is followed by a second of said four human IgE CH3 domains which is followed by a third of said four human IgE CH3 domains which is followed by a second of said three non-placental mammalian IgE domains which is followed by a fourth of said four human IgE CH3 domains which is followed by a third of said three non-placental mammalian IgE domains.

69. (New) The immunogenic polypeptide of claim 68, wherein said first of said three non-placental mammalian IgE domains is an opossum IgE CH2 domain, wherein said second of said three non-placental mammalian IgE domains is an opossum IgE CH2 domain, and wherein said third of said three non-placental mammalian IgE domains is an opossum IgE CH4 domain.

70. (New) The immunogenic polypeptide of claim 55, wherein said immunogenic polypeptide comprises a polyhistidine sequence.

71. (New) The immunogenic polypeptide of claim 55, wherein said immunogenic polypeptide is capable of dimerizing.

72. (New) An immunogenic polypeptide comprising at least an N-terminal half of a human IgE CH3 domain located between two non-placental mammalian IgE domains, wherein said immunogenic polypeptide is effective to induce an anti-human IgE response in a human.

73. (New) The immunogenic polypeptide of claim 72, wherein each of said two non-placental mammalian IgE domains has an IgE sequence present in a non-placental mammal selected from the group consisting of opossum, platypus, koala, kangaroo, wallaby, and wombat.

74. (New) The immunogenic polypeptide of claim 72, wherein one of said two non-placental mammalian IgE domains is a non-placental mammalian IgE CH2 domain.

75. (New) The immunogenic polypeptide of claim 72, wherein one of said two non-placental mammalian IgE domains is a non-placental mammalian IgE CH4 domain.

76. (New) The immunogenic polypeptide of claim 72, wherein one of said two non-placental mammalian IgE domains is a non-placental mammalian IgE CH2 domain, and the other of said two non-placental mammalian IgE domains is a non-placental mammalian IgE CH4 domain.

77. (New) The immunogenic polypeptide of claim 72, wherein one of said two non-placental mammalian IgE domains is an opossum IgE CH2 domain.

78. (New) The immunogenic polypeptide of claim 72, wherein one of said two non-placental mammalian IgE domains is an opossum IgE CH4 domain.

79. (New) The immunogenic polypeptide of claim 72, wherein one of said two non-placental mammalian IgE domains is an opossum IgE CH2 domain, and the other of said two non-placental mammalian IgE domains is an opossum IgE CH4 domain.

80. (New) The immunogenic polypeptide of claim 72, wherein said immunogenic polypeptide comprises a polyhistidine sequence.

81. (New) The immunogenic polypeptide of claim 72, wherein said immunogenic polypeptide is capable of dimerizing.

82. (New) An immunogenic polypeptide comprising a means for providing a human IgE CH3 polypeptide to a human connected to a non-placental mammalian means for inducing an anti-human IgE response in said human.

83. (New) An immunogenic polypeptide consisting of a human IgE CH3 domain, an opossum IgE CH2 domain, and an opossum IgE CH4 domain, wherein said human IgE CH3 domain is located between said opossum IgE CH2 domain and said opossum IgE CH4 domain.